Biocept got patent for its Molecular Biomarker Technology

January 8, 2018 | Monday | News

Expands intellectual property position to 22 issued patents globally for Biocept's highly sensitive methods for detecting cancer biomarkers in circulating tumor DNA (ctDNA) and on circulating tumor cells (CTCs)

Biocept, Inc. is a molecular diagnostics company with commercialized assays for lung, breast, gastric, colorectal and prostate cancers, and melanoma.

The Company leverages its proprietary liquid biopsy technology to provide physicians with clinically actionable information for treating and monitoring patients diagnosed with cancer.

The company announced the issuance of Australian Patent No. 2012250516, entitled METHODS FOR DETECTING NUCLEIC ACID SEQUENCE VARIANTS.

This is the second issued patent for Biocept's Target Selector™ assays for molecular analysis using real-time PCR, Sanger sequencing and next generation sequencing (NGS).

Consistent with Biocept's recently issued U.S. patent, the Australian patent encompasses Biocept's proprietary "switch-blocker" technology,

It enhances the patient specimens for oncogene mutations of interest, resulting in ultra-high sensitivity and specificity for the detection of cancer associated mutations found in blood, tissue, and other biological sources.

Sign up for the editor pick and get articles like this delivered right to your inbox.

+Country Code-Phone Number(xxx-xxxxxxx)

Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account

Podcast

Survey Box

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls